SCHEMBL5233075

SCHEMBL5233075

CCCCOc1c(CNC(=O)OC(C)(C)C)n(CC2CC2)c(=O)c2ccc(C(=O)O)cc12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.36
ACACA Q13085 2/20 0.36
HIF1A Q16665 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.35
CYP1A1 P04798 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2B6 P20813 1/20 0.35
CYP2C19 P33261 1/20 0.35
CYP3A43 Q9HB55 1/20 0.35
DRD2 P14416 1/20 0.34
NPC1 O15118 1/20 0.34
GSK3B P49841 1/20 0.34
CNR2 P34972 1/20 0.34
BRD4 O60885 1/20 0.33
PTGER4 P35408 1/20 0.33
TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5236207 0.93 NPC1 (0.42) HIF1ACYP1A1CYP2D6CYP2B6CYP2C19
SCHEMBL5238626 0.93 KDM4E (0.36) HIF1AKDM4EALDH1A1GAAHPGD
SCHEMBL5232143 0.88 KDM4E (0.37) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL5231264 0.87 DPP4 (0.46) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL5234879 0.80 KDM4E (0.38) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL5234020 0.80 GSK3B (0.37) HIF1AKDM4EALDH1A1HPGDHSD17B10
SCHEMBL5237159 0.80 DPP4 (0.47) CYP1A1CYP2D6CYP2B6CYP2C19CYP3A43
SCHEMBL5236869 0.80 ALDH1A1 (0.39) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL5234694 0.79 MAPK8 (0.45) KDM4EALDH1A1HPGDHSD17B10GSK3B
SCHEMBL5238616 0.78 PGR (0.39) HIF1AKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-7034039-B2 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-04-25 US disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed
WO-2002062764-A9 FUSED HETEROCYCLIC COMPOUNDS TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2002-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 ACACB 3065/4885ACACA 2224/4885HIF1A 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.